Half Yearly Report and Accounts
Released
Released
Announcement PDF
Appendix 4D
Half-yearly report
Emyria Limited
ABN 96 625 085 734
1. Company details
Name of entity:
ABN:
Reporting period:
Previous period:
Emyria Limited
96 625 085 734
For the half-year ended 31 December 2020
For the half-year ended 31 December 2019
2. Results for announcement to the market
31 Dec 2020
31 Dec 2019
% change
Revenues from ordinary activities
2,110,803
905,627
+133%
Loss from continuing operations after tax attributable to the
owners of Emyria Limited
(2,073,216)
(2,141,747)
-3%
Loss for the half-year attributable to the owners of Emyria
Limited
(2,076,332)
(2,141,747)
-3%
3. Net tangible assets per security
Net tangible (liability)/asset per ordinary security
31 Dec 2020
Cents
31 Dec 2019
Cents
2.27
(1.08)
4. Dividends
No dividends were paid during the current or previous financial years and no dividends have been declared subsequent
to the financial year end and up to the date of this report.
Emyria Limited
Appendix 4D
Half-year report
5. Dividend reinvestment plans
There are no dividend or distribution reinvestment plans in operation.
6. Foreign entities
Not applicable.
7. Gain or loss of control over entities
There were no entities over which control was gained or lost during the half-year ended 31 December 2020.
8. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The financial statements were subject to a review by the auditors and the review report is attached as part of the
Interim Report.
9. Attachments
Details of attachments (if any):
The Interim Report of Emyria Limited for the half-year ended 31 December 2020 is attached.
10. Signed
Michael Winlo
Managing Director
Perth
Date: 24 February 2021
ASX Announcement
24/02/2021
Emyria in strong position to deliver on drug registration priorities
Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development
company, announces its results for the half year ended 31 December 20.
Highlights:
●
Operating profit of $100k compared to a loss in prior comparative period (pcp)
(31 December 2019: -$496k)
●
Operating sales of $1.1m representing growth of 165% pcp
(31 December 2019: $0.4m)
●
Operating costs of $1m, 13% increase on pcp (31 December 2019: $0.9m)
●
Significant investment into research and development representing an increase of
329% on pcp, leading to:
o
Launch of first IP and data-backed drug development programs:
▪
EMD-003, targeting mental health and;
▪
EMD-004, targeting irritable bowel syndrome
o
Successful grant award for Emyria’s remote monitoring platform
▪
$880k over 2 years to monitor clinical and mental health in vulnerable
patients
o
Expansion of Emyria Data - Real-World Evidence asset covering over 3,000
patients and growing
o
Partnership with Mind Medicine Australia to develop an evidence-generating
care model for psychedelic-assisted therapy
●
Cash position of $4.8m representing an increase of 32% on pcp
(31 December 2019: $3.7m)
●
Working capital increase of only 1% on pcp that demonstrates Emyria’s
management of its debtors and creditors
1H20 review and FY20 outlook
Commenting on the 1H20 results and outlook for the business, Emyria’s Managing Director,
Dr Michael Winlo, said: “Emyria’s strategic investments into growing and improving our
data asset were validated by the launch of our own, independent, drug development
programs targeting major under-served medical needs. Each program is being backed by
IP and insights from internal analysis performed on our proprietary data asset. Our first
program EMD-003, is targeting registration as a Schedule 3 cannabidiol (CBD) medicine
and will benefit from the TGA decision to deschedule low-dose CBD. Schedule 3 medicines
are managed by Pharmacists, are available over-the-counter and do not require a
prescription from a doctor.
1
In addition, our TGA-registered remote monitoring system and service, Openly, was
recognised in a major successful grant award and we continue to expand our care model to
promising new therapy areas with a partnership with Mind Medicine Australia.
Meanwhile, patient demand for our care model continues to increase which led to record
clinic utilisation and our first operational profit for the quarter and a strong cash position.
We are focussed on delivering and completing the required pivotal clinical trials required to
successfully register EMD-003 and further expanding our clinical services nationally to meet
demand.”
This announcement has been approved and authorised for release by the Board of Emyria
Limited.
For further information:
Dr Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au
Andrew Williams
Media Relations
+61 (0) 412 614 125
andreww@profilemedia.com.au
About Emyria (www.emyria.com)
Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target
unmet needs and are focused on obtaining approval from major global regulators. Emyria’s
drug development programs are informed by insights generated from extensive analysis of
Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across
Emyria’s independent clinical services (Emerald Clinics - www.emeraldclinics.com.au)
Emyria Data provides deep treatment insights and is therefore a source of unique IP,
strategically designed drug development and personalised care programs.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company,
the company’s strategy, future operations, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements.
Actual results may differ materially from those indicated by such forward-looking statements as a
result of various important factors, including: the Company’s ability to successfully develop its product
candidates and timely complete its planned clinical programs and the Company’s ability to obtain
marketing approvals for its product candidates. In addition, the forward-looking statements included
in this press release represents the Company’s views as of the date hereof. The Company anticipates
that subsequent events and developments will cause the Company’s views to change. However, while
the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not
be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
2
HALF YEAR END FINANCIAL REPORT 31·DEC·20
ABN 96·625·085·734
HALF YEAR FINANCIAL REPORT
FOR THE HALF YEAR ENDED 31 DECEMBER 2020
CONTENTS
CORPORATE DIRECTORY ..................................................................................................................................... 2
DIRECTORS’ REPORT…. .............................................................................................................................................3
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME . .....................................9
CONSOLIDATED STATEMENT OF FINANCIAL POSITION .......................................................................................10
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY ........................................................................................11
CONSOLIDATED STATEMENT OF CASH FLOWS ...................................................................................................13
CONDENSED NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS ...............................................................14
DIRECTORS’ DECLARATION................................................................................................................................24
AUDITOR’S INDEPENDENCE DECLARATION ........................................................................................................25
INDEPENDENT AUDITOR’S REVIEW REPORT TO THE MEMBERS ...........................................................................26
CORPORATE DIRECTORY
Directors
Dr Stewart Washer
Executive Chairman
Dr Michael Winlo
Managing Director
Dr Alistair Vickery
Executive Director
Mr Matthew Callahan
Non-Executive Director
Sir Professor John Tooke Non-Executive Director
Company Secretary
Simon Robertson
Principal and Registered Office
Suite 3, 43 Oxford Close
West Leederville, Western Australia 6007
Telephone: +61 8 6559 2800
Website: www.emyria.com
Auditor
Stantons International
Level 2, 1 Walker Avenue
West Perth, Western Australia 6005
Telephone: (08) 9481 3188
Share Registry
Automic Pty Ltd
Level 2, 267 St Georges Terrace
Perth, Western Australia 6000
Telephone: 1300 288 664
Securities Exchange Listing
Emyria Limited shares are listed on the Australian Securities Exchange
ASX Code
EMD - ordinary shares
DIRECTORS’ REPORT
The Directors of Emyria Limited present their report on Emyria Limited (“Company” or “Emyria”) and the entities
it controlled (“Consolidated Entity” or “Group”) at the end of, or during, the half year ended 31 December 2020.
Directors
The names and details of the Directors in office during the half year ended 31 December 2020 and until the date
of this financial report are as follows. The Directors were in office for the entire period unless otherwise stated.
Dr Stewart Washer
Dr Michael Winlo
Dr Alistair Vickery
Mr Matthew Callahan
Professor Sir John Tooke
Principal Activities
The principal continuing activity of the Group is clinical and data services.
Review of Operations
Operating Result
The loss from continuing operations for the half year ended 31 December 2020 after providing for income tax
amounted to $2,073,216 (2019: $2,141,747).
Key Highlights:
x Operating profit of $100k compared to loss in prior comparative period (pcp) (31 December 2019: -$496k)
x
Operating sales of $1.1m representing growth of 165% pcp (31 December 2019: $0.4m)
x
Operating costs of $1m only 13% increase on pcp (31 December 2019: $0.9m)
x
Cash position of $4.8m representing an increase of 32% on pcp (31 December 2019: $3.7m)
x
Working capital increase of only 1% on pcp demonstrates s management of its debtors and creditors
x
Significant investment into research and development representing an increase of 329% on pcp
Launch of EMD-003 - a cannabinoid treatment for mental health
EMD-003 is Emyria’s leading cannabinoid drug program seeking registration as a Schedule 3 medicine. EMD-003
is targeting the treatment of psychological distress and the symptoms of anxiety, depression and stress for
certain patient populations. Schedule 3 medicines are Pharmacist-managed and available over-the-counter.
Analysis of Emyria’s data has identified specific patient populations that appear to have a safe and favourable
response to specific doses of CBD. Specific patents, covering these insights, have been filed. The Company
believes a strong IP portfolio will be important in cannabinoid medicine development since neither of the two
main ingredients in medicinal cannabis - CBD or THC - can be patented as chemical entities. Therefore, IP is
restricted to dose formulations and “methods of use” which describe how the treatments may be effectively
and safely administered to specific patients to treat specific conditions.
Mental health is also a rising global health challenge, particularly in the last 12 months. In the 2017-2018
National Health survey, mental health topped the list of chronic health conditions in Australia affected 4.8
million people, or 20.1% of all Australians. In any one year over 2 million Australians suffer from anxiety
alone. Psychological distress, in particular, has been increasing in incidence.
3
DIRECTORS’ REPORT
Review of Operations (continued)
Launch of EMD-004 - a cannabinoid treatment for irritable bowel syndrome
EMD-004 is a cannabinoid-based medicine focused on treating symptoms associated with irritable bowel
syndrome - a large unmet need.
IBS is common and affects around 3 out of every 10 people. In Australia there are no medicines designed
specifically for IBS. Emyria’s observational trial on IBS has ethics approval and recruiting is underway.
Expansion of in-house analytical team
In the December quarter, Emyria expanded our in-house analytics team with additional PhD level expertise in
biostats and behavioural economics. Emyria also engaged Bayesian Intelligence [BI] - experts in Bayesian
network modelling and real-world problem solving - to commence design and development of a proprietary
clinical decision support system.
TGA registration and development of Openly – remote monitoring for clinical and mental health
Emyria continues to support strategic development into its remote monitoring platform - Openly - with an
application for Class II TGA registration submitted in the December quarter for the platform’s smartphone-led
heart rate and heart rate variability measurement technology. These vital sign measures are related to
psychological distress - which can be early signs of infection or mental health changes. The Company believes
these measures will be important to the development of EMD-003.
The company continues to work with Mt Sinai hospital (NY) on the development of this technology and has
applied for a number of grants to further develop Openly and its application to mental health.
Growing clinical engagement across Australia
Emerald Clinics’ doctors provide in-depth, long-term, individualised care for unresolved patient conditions. Our
model ensures each patient receives attentive, personalised care and also assists us to complete our
comprehensive set of validated clinical assessments which contribute to our Emyria Data asset. Patient demand
for our clinical services continued to grow.
Partnership with Mind Medicine Australia
Emyria will design a care model describing how psychedelic-assisted therapies could be delivered safely to
patients with major mental health concerns. Mind Medicine Australia will provide access to its international
network of experts, clinical trainers and treatment model strategies. The model will start with psilocybin and
MDMA-assisted therapies and draw on pivotal research conducted recently in North America and Europe.
Emyria will also apply its remote monitoring technology and lead the construction of a longitudinal data registry.
The registry will collect real world clinical data on diagnoses, concomitant medications, dosing information and
patient responses to psychedelic-assisted treatments as measured using validated clinical and patient-reported
endpoints. The data will support ongoing research into the safety, effectiveness and cost benefits of
psychedelic-assisted therapies for major mental health concerns compared to current alternatives.
4
DIRECTORS’ REPORT
Review of Operations (continued)
1H20 review and FY20 outlook
Commenting on the 1H20 results and outlook for the business, Emyria’s Managing Director, Dr Michael
Winlo, said:
“Emyria’s strategic investments into growing and improving our data asset were validated by the launch
of our own, independent, drug development programs targeting major under-served medical
needs. Each drug development program is being backed by unique intellectual property and insights
from internal analysis we have performed on our proprietary data asset.
Our first program EMD-003, is targeting registration as a Schedule 3 cannabidiol (CBD) medicine and
will benefit from the TGA decision to reschedule low-dose CBD.
In addition, our TGA-registered remote monitoring system and service, Openly, was recognised in a
major successful grant award and we continue to expand our care model to promising new therapy
areas with a partnership with Mind Medicine Australia.
Meanwhile, patient demand for our care model continues to increase which led to record clinic
utilisation and our first operational profit for the quarter and a strong cash position.
We are focussed on delivering and completing the required pivotal clinical trials required to successfully
register EMD-003 and further expanding our clinical services nationally to meet demand.”
5
DIRECTORS’ REPORT
Dividends
No dividends were paid or proposed to be paid to members during the half year ended 31 December 2020.
Significant Changes in the State of Affairs
The impact of the Coronavirus (COVID-19) pandemic is ongoing and while it has been financially neutral for the
Group up to 31 December 2020, it is not practicable to estimate the potential impact, positive or negative, after
the reporting date. The situation is rapidly developing and is dependent on measures imposed by the Australian
Government and other countries, such as maintaining social distancing requirements, quarantine, travel
restrictions and any economic stimulus that may be provided.
On 10 August 2020, the Group announced on the ASX that it would be entering into a Real-World Evidence
contract with Spectrum Biomedical UK (“SBUK”) which is a subsidiary of Canopy Growth Corp (a Toronto
Exchange Security listed company TSX:TSE). Emerald will be responsible for collection of specific data points
including de-identified patient information, use of concomitant medicines, prescribed usage and diagnoses, and
a rate of patient reported outcome measures. This data will then be provided to SBUK as a per patient pricing
model. The contract value is up to GBP 400,000 (~AUD 723,000) the Group received GBP 150,000 (~AUD
270,000) up front plus GBP 300 (~AUD 542) per patient. The contract term is 24 months.
On 14 August 2020, the Group changed its name from “Emerald Clinics Limited” to “Emyria Limited”.
On 7 September 2020, the Company had issued 27,500,000 shares at $0.08 per share, raising $2,200,000 (before
costs).
On 30 September 2020, the Group announced that it had entered into a data agreement with Zelira Therapeutics
Limited that were in relation to chronic insomnia. The contract value is for the Group to receive up to $100,000
over a period of 12 months. The Group recognised $50,000 revenue from this agreement for the half-year ended
31 December 2020.
On 21 October 2020, the Group announced that it had entered into a services agreement with Sapphire Medical
Clinics to obtain new sources of data in the UK. The contract value is for the Group to pay to Sapphire Medical
Clinics up to £260,000 for over a period of 24 months.
On 2 November 2020, the Group received the R&D refund of $954,180 for the financial year ended 30 June 2020.
From the funds received, the Group has repaid the $259,638 drawn under its R&D credit facility with Radium
Capital.
On 9 November 2020, the Group announced that it had entered into a data agreement with Zelira Therapeutics
Limited that were in relation to autism. The contract value is for the Group to receive up to $115,000 over the
first 6 months as well as subscription fee for each patient enrolled in the study, up to a maximum of 150
participants. The term of the agreement is a period of 12 months. The Group recognised revenue of $65,000
from this agreement for the half-year ended 31 December 2020.
On 13 November 2020, the Company issued 12,000,000 options to the Director and employees of the Company
for an exercise price of $0.114 per share and expiring on 13 November 2024. The vesting conditions are:
x One third immediately on issue;
x One third one year from date of issue subject to continued employment or service and;
x One third two years from date of issue subject to continued employment or service.
On 22 December 2020, the Company issued 500,000 options to Professor Bruce Robinson, a consultant to the
Company, for an exercise price of $0.114 per share and expiring on 22 December 2023. The vesting conditions
are:
x One third immediately on issue;
x One third one year from date of issue subject to continued employment or service and;
6
DIRECTORS’ REPORT
Significant Changes in the State of Affairs (continued)
x
One third two years from date of issue subject to continued employment or service.
On 22 December 2020, the Company had issued 14,117,650 shares at $0.085 per share, raising $1,200,000
(before costs) and 1-for-3 free attaching unlisted options exercisable at $0.20 per option, expiring 2 years from
the date of issue. The lead manager, 62 Capital Pty Ltd also received 6,000,000 unlisted options as placement
fees which vested immediately for an exercise price of $0.20 per share and expiring on 22 December 2022.
Apart from the above, there are no other matters or circumstances that have arisen since the end of the financial
year which have significantly affected or may significantly affect the operations of the Group, the results of those
operations, or the state of affairs of the Group in future financial periods.
After Balance Date Events
Successful grant award for Emyria’s remote monitoring platform
Emyria will play a central role in a $880k Future Health Research and Innovation Grant award. Emyria to receive
between $320,000 and $400,000 over two years - depending on final contract arrangements - to monitor clinical
and mental health in vulnerable patients using the Openly platform.
The successful grant is titled “An advanced digital monitoring and engagement platform for at-risk and
confirmed COVID-19 individuals” and is intended to boost Western Australia’s digital health infrastructure and
capacity to manage future health challenges like COVID-19.
The aims of the grant are to evaluate the utility of advanced digital health monitoring in vulnerable patient
populations, to improve engagement amongst aged and ethnic populations and to improve mental health
evaluation and monitoring for those under remote care.
Emyria will take a leadership role in the grant and will lead a multidisciplinary collaboration involving the state’s
major health services and universities. The grant will also extend Emyria’s collaboration with Mt Sinai, New York.
Apart from the above, there has been no matter or circumstance that has arisen since 31 December 2020 that
has significantly affected, or may significantly affect:
x the Group’s operations in future financial years;
x the result of those operations in future financial years; or
x the Group’s state of affairs in future financial years.
7
DIRECTORS’ REPORT
Likely Developments and Expected Results of Operation
The Group will focus on developing its business which combines the treatment of patients and the capture
of high-quality clinical data to transform the way novel therapies are understood and researched. The
Group will then combine this data with health records and published information to generate powerful
data sets that provide actionable insights for physicians, drug developers, research groups and government
departments. The data asset developed, and associated technologies, will form the primary source of
income for the Group, generating license usage fees and royalties from third parties via a data-insights-asa-service offerings while also developing more effective clinical models internally.
Auditor’s Independence Declaration
A copy of the Auditor’s Independence Declaration as required under Section 307C of the Corporations Act 2001
is set out on page 25 of the interim financial report.
Signed in accordance with a resolution of the Board of Directors.
Michael Winlo
Director
Perth
24 February 2021
8
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE HALF YEAR ENDED 31 DECEMBER 2020
31 December
2020
$
31 December
2019
$
Revenue
Sales
Operating costs
1,146,731
(1,046,731)
432,837
(929,051)
Gross profit/(loss)
100,000
(496,214)
Other Revenue
Interest
Research and Development grant received
9,892
954,180
4,613
468,177
Expenses
Research and Development expenses
Employee wages and director fees
Travel and conference expenses
Corporate compliance costs
Administration costs
IT consultancy fees
Consultancy fees
Finance costs
Share based payments
Depreciation and amortisation expense
Fixed assets write off
(1,611,913)
(501,642)
(10,112)
(240,217)
(61,011)
(32,541)
(173,589)
(31,476)
(210,654)
(158,259)
(105,874)
(375,732)
(803,684)
(171,457)
(225,270)
(110,290)
(63,537)
(122,405)
(17,807)
(42,148)
(185,993)
-
Total Expenses
(3,137,288)
(2,118,323)
Loss before income tax
(2,073,216)
(2,141,747)
Income tax expense
-
-
Loss for the period
(2,073,216)
(2,141,747)
(3,116)
-
(2,076,332)
(2,141,747)
Cents
(1.00)
(1.00)
Cents
(1.64)
(1.64)
Notes
Other comprehensive income for the half year
Items that may be classified to profit or loss
Exchange differences on translation of foreign operations
Total Comprehensive loss for the period attributable
to the members of Emyria Limited
10
4
Loss per share for the period attributable to the Members of Emyria
Limited
Basic loss per share
Diluted loss per share
The above consolidated statement of profit or loss and other comprehensive income should be read in
conjunction with the accompanying notes.
9
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2020
Notes
CURRENT ASSETS
Cash and cash equivalents
Trade and other receivables
Other current assets
2
TOTAL CURRENT ASSETS
NON-CURRENT ASSETS
Restricted cash
Right-of-use assets
Property, plant and equipment
Intangible assets
3
4
5
TOTAL NON-CURRENT ASSETS
TOTAL ASSETS
31 December
2020
$
30 J u n e
2020
$
4,869,635
125,540
91,284
3,686,333
121,615
31,433
5,086,459
3,839,381
113,181
238,396
450,418
154,656
156,558
323,390
598,305
147,310
956,651
1,225,563
6,043,110
5,064,944
CURRENT LIABILITIES
Trade and other payables
466,125
461,124
Provisions
146,256
142,088
109,004
-
152,689
247,154
721,385
1,003,055
29,000
68,000
180,005
210,972
TOTAL NON-CURRENT LIABILTIES
209,005
278,972
TOTAL LIABILITIES
930,390
1,282,027
5,112,720
3,782,917
14,865,833
373,202
(10,126,315)
11,751,953
84,063
(8,053,099)
5,112,720
3,782,917
Lease liabilities
Borrowings
6
7
TOTAL CURRENT LIABILITIES
NON-CURRENT LIABILITIES
Make good provision
Lease liabilities
6
NET ASSETS
EQUITY
Share capital
Reserves
Accumulated losses
TOTAL EQUITY
8
9
The above consolidated statement of financial position should be read in conjunction with the accompanying
notes.
10
-
Other comprehensive loss
Total comprehensive loss for the period
14,865,833
3,113,880
376,318
292,255
292,255
-
-
-
-
84,063
Share based
payment
Reserves
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.
Balance at 31 December 2020
Total contributions by and distributions to owners
-
(286,120)
Transaction costs from issued capital
Issue of share based payments
3,400,000
Proceeds from issued capital
Contributions by and distributions to owners
Transactions with owners, recorded directly in equity
-
11,751,953
Share capital
Loss after income tax for the half year
Balance at 1 July 2020
in $ dollars
Attributable to equity holders of the Group
(3,116)
-
-
-
-
(3,116)
(3,116)
-
-
Foreign
Currency
Translation
Reserve
(10,126,315)
-
-
-
-
(2,073,216)
(2,073,216)
(8,053,099)
Accumulated
losses
Total
5,112,720
3,406,135
292,255
(286,120)
3,400,000
(3,116)
(2,076,332)
(2,073,216)
3,782,917
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE HALF YEAR ENDED 31 DECEMBER 2020
11
3,060,526
187,788
-
(312,212)
46,883
42,148
42,148
-
-
-
-
4,735
-
4,735
Share based
payment
Reserves
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.
Balance at 31 December 2019
Total contributions by and distributions to owners
Issue of share based payments
Transaction costs from issued capital
Proceeds from issued capital
500,000
-
Total comprehensive loss for the period
Transactions with owners, recorded directly in equity
Contributions by and distributions to owners
-
2,872,738
-
2,872,738
Share capital
Loss after income tax for the half year
Balance at 1 July 2019, restated
Adjustment on initial application of new accounting standards (AASB
16)
Balance at 1 July 2019
in $ dollars
Attributable to equity holders of the Group
369,334
-
-
-
-
-
-
369,334
-
369,334
Convertible
Notes Reserve
(4,916,963)
-
-
-
-
(2,141,747)
(2,141,747)
(2,775,216)
(27,948)
(2,747,268)
Accumulated
losses
(1,440,220)
229,936
42,148
(312,212)
500,000
(2,141,747)
(2,141,747)
471,591
(27,948)
499,539
Total
12
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE HALF YEAR ENDED 31 DECEMBER 2019
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE HALF YEAR ENDED 31 DECEMBER 2020
31 December
2020
$
31 December
2019
$
Receipts from customers
1,261,820
427,068
Cash paid to suppliers and employees
(3,887,926)
(2,519,027)
Interest received
9,892
4,613
Interest and other finance costs paid
(9,147)
(9,980)
R&D refund received
954,180
468,177
(1,671,181)
(1,629,149)
-
(17,631)
Payments for intangible assets
(40,429)
-
Net cash (used in) investing activities
(40,429)
(17,631)
Proceeds from issue of shares
3,400,000
500,000
Transaction costs paid from the issue of shares
(204,519)
(136,704)
Repayment of Borrowings
(259,638)
-
Repayment of lease liabilities
(73,828)
(112,978)
Net receipts/(payments) for cash backed guarantees
43,376
(50,300)
Net cash provided by financing activities
2,905,391
200,018
Net increase/(decrease) used in cash and cash equivalents
1,193,781
(1,446,762)
Effects of exchange rate changes on cash and cash equivalents
(10,479)
-
Cash and cash equivalents at 1 July
3,686,333
2,608,814
Cash and cash equivalents at 31 December
4,869,635
1,162,052
Notes
Cash flows from operating activities
Net cash (us
Share your feedback
Discover